Raymond James raised the firm’s price target on Adma Biologics to $10 from $8 and keeps a Strong Buy rating on the shares. Adma Biologics delivered another strong beat-and-raise quarter with EPS, revenue, and adjusted EBITDA all beating consensus estimates, the analyst tells investors in a research note. Operating leverage continues to get better and manufacturing yield enhancements represent further upside to guidance, the firm adds.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADMA:
- Biotech Alert: Searches spiking for these stocks today
- ADMA Biologics to Report First Quarter 2024 Financial Results on May 9, 2024
- Kaitlin Kestenberg Promoted to COO at ADMA Biologics
- ADMA Biologics price target raised to $7.50 from $6 at H.C. Wainwright
- ADMA Biologics announces FDA approval of sBLAs for ASCENIV, BIVIGAM